Gemcitabine-Induced Acute Coronary Syndrome: A Case Report

Banu Ozturk\textsuperscript{a} Gulten Tacoy\textsuperscript{b} Ugur Coskun\textsuperscript{a} Emel Yaman\textsuperscript{a} Giray Sahin\textsuperscript{a} Suleyman Buyukberber\textsuperscript{a} Ramazan Yildiz\textsuperscript{a} Ali O. Kaya\textsuperscript{a} Salih Topal\textsuperscript{b} Murat Ozdemir\textsuperscript{b} Mustafa Benekli\textsuperscript{a}

Departments of \textsuperscript{a}Medical Oncology and \textsuperscript{b}Cardiology, Gazi University Medical School, Ankara, Turkey

Case Report

Introduction

Gemcitabine, an analogue of deoxycytidine, exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S phase) and also blocking the progression of cells through the G1/S phase boundary. Gemcitabine exhibits clinical activity in a variety of tumors including pancreatic, ovarian, breast, bladder, non-small cell lung cancer and small cell lung cancer\cite{1, 2}. In metastatic soft tissue and bone sarcomas refractory to standard chemotherapy, gemcitabine was effective in achieving disease stabilization and effected a minimal response in several phase II studies\cite{3}. Gemcitabine is well tolerated by patients; myelosuppression (especially thrombocytopenia) is its dose-limiting side effect. Other side effects including nausea, vomiting, rash, fever, and alopecia are mild or moderate. Drug-induced pulmonary toxicity is a rare but important complication of gemcitabine administration\cite{4}. The elevation of serum transaminases, hematuria, proteinuria are rare and not severe. The most common cardiotoxic effect due to antimetabolites is coronary ischemia\cite{5}. There are only a few case reports of cardiovascular adverse effects associated with gemcitabine in the literature.

Case Report

A 59-year-old woman was admitted to the hospital for bilateral pulmonary nodules. Fluorine-18-deoxy-fluoro-D-glucose ($^{18}$F-FDG) PET-CT scanning revealed $^{18}$F-FDG uptake in pulmonary nodules.
nodules. Before diagnostic procedures for these nodules, she had mild to moderate chest pain. A coronary angiography was performed and revealed 80% stenosis in the bifurcation of the left anterior descending artery and the first diagonal branch. She had hypertension, diabetes mellitus, a family history of coronary artery disease, and hyperlipidemia. Medical treatment with aspirin, beta-blocker and nitrate was initiated. After cardiac stabilization, fine-needle aspiration biopsy was performed from the pulmonary nodules and metastatic leiomyosarcoma was diagnosed. She was asymptomatic and refused anticancer therapy. A mass on her right shoulder and another on her scalp developed 1 year later; both were excised and pathological findings were consistent with leiomyosarcoma. Multiple pulmonary metastases and a mass about 5 cm in diameter near the liver and diaphragm were detected in chest and abdominal CT scans. She received two courses of ifosfamide, but the abdominal mass progressed and a new chemotherapy regimen consisting of docetaxel and gemcitabine was begun. She received 900 mg/m² gemcitabine i.v. over 90 min on days 1 and 8, 100 mg/m² docetaxel i.v. over 1 h on day 8. Three days after administration of docetaxel and gemcitabine and on the 8th day of therapy, she experienced mild chest pain, which resolved spontaneously. She was admitted to the hospital for a second cycle of chemotherapy and hospitalized for close monitoring. After 30 min of gemcitabine infusion, she experienced severe chest pain accompanied by acute left bundle-branch block (LBBB, fig. 1). She was transferred to the coronary care unit where she received anticoagulant and antithrombotic therapy consisting of aspirin, clopidogrel, a heparin infusion, and beta-blocker nitrate treatment. Within 10 min of admission to the coronary care unit, her chest pain resolved and LBBB disappeared (fig. 2). Her physical examination was normal; she had an ejection fraction of 0.60 on echocardiogram. Her laboratory findings were in the normal range. Levels of troponin T, creatinine kinase and MB fractions were within normal limits at 6 and 12 h. A selective coronary angiography showed 80% stenosis in the bifurcation of the left anterior descending artery and the first diagonal branch, which was

Fig. 1. ECG after gemcitabine infusion showed LBBB.
Fig. 2. ECG after anticoagulant and antithrombotic therapy; LBBB disappeared.
successfully treated with percutaneous coronary intervention. She was discharged after 2 days without any adverse cardiac events with antiaggregant (aspirin, clopidogrel), beta-blocker nitrate treatment. No additional anticancer therapy was given and she died 5 months later due to disease progression.

**Discussion**

Cardiotoxicity is a significant complication of chemotherapy. Cardiac events may include mild blood pressure changes, thrombosis, electrocardiographic changes, arrhythmias, myocarditis, pericarditis, myocardial infarction, cardiomyopathy, cardiac failure (left ventricular failure) and congestive heart failure [5, 6]. These may occur during or shortly after treatment, within days or weeks after treatment, or may not be apparent until months, and sometimes years after the completion of chemotherapy [5, 6]. Factors attributable to the drug (such as type of drug, cumulative or total dose and schedule) and patient characteristics including age, prior chest-mediastinal irradiation history, concurrent administration of cardiotoxic agents, electrolyte imbalances such as hypokalemia and hypomagnesemia, history of cardiac diseases and other risk factors of atherosclerosis influence the incidence and severity of chemotherapy-induced adverse cardiac reactions [5, 6]. Our case concerned a woman with a history of coronary artery disease who developed acute coronary syndrome after chemotherapy although already receiving antithrombotic, beta-blocker and nitrate therapy.

Anthracycline-induced cardiomyopathy is the most well-known cardiac event [6]. Alkylation agents such as cyclophosphamide, ifosfamide, cisplatin and other agents including paclitaxel, etoposide, teniposide, the Vinca alkaloids, fluorouracil are known to cause several adverse cardiac effects [5, 6]. Fluoropyrimidines can cause angina such as chest pain, myocardial infarction and sudden cardiac death. 5-Fluorouracil (5-FU) belongs to the group of pyrimidine analogues, and although cardiac toxicity occurs in 1–3% of patients, the incidence of acute coronary syndrome during 5-FU treatment is very low [7]. Underlying mechanisms of cardiac ischemia are still unknown. The most likely mechanism is coronary vasospasm. Transient coronary vasospasm may cause stable or unstable angina pectoris, whereas persistent vasospasm may result in acute myocardial infarction (AMI). Canale et al. [8] reported a subject developing AMI during 5-FU infusion who did not have classic risk factors for coronary heart disease and no evidence of coronary stenosis on coronary angiography. This finding is supported by the probability of coronary spasm due to 5-FU infusion. Capecitabine, an oral fluoropyrimidine, is a prodrug that metabolizes to 5-FU. Several case reports demonstrated acute coronary syndrome related to capecitabine treatment; similarly 5-FU coronary vasospasm was the most likely reason of this acute adverse cardiac event [9].

Gemcitabine-induced acute coronary syndromes are rarely described in the literature. Bdair et al. [10] reported a case with previous myocardial infarction history, which developed AMI 3 days after gemcitabine therapy. Our subject, who had a history of coronary artery disease, developed chest pain with accompanying newly developed LBBB shortly after drug infusion, but no biomarker increases were observed and both symptoms and LBBB resolved with antianginal treatment. We speculate that gemcitabine-induced coronary vasospasm combined with pre-existing coronary artery disease was the cause of the acute coronary syndrome, which subsequently was treated by antianginal therapy and percutaneous coronary intervention. Dumontet et al. [11] reported a case with gemcitabine-induced AMI in which previous cardiac disease was known and AMI occurred 4 days after infusion of gemcitabine. In contrast to previous reports, in our case, acute coronary syndrome developed during the treatment. Similarly, in a case report by Kalapura et al. [12], a coronary event was documented 6 h after the fifth cycle of gemcitabine; interestingly there was no cardiac history in this case.

The mechanism of gemcitabine-induced coronary ischemia is still unclear. Similar to 5-FU, coronary spasm is possible. Endothelial dysfunction and coronary thrombosis are other potential explanations. Physicians should take the rare but severe complication of gemcitabine treatment into consideration as intensive cardiac monitoring is essential to prevent the development of fatal cardiac complications, including AMI and severe arrhythmias, particularly in patients with cardiac disease and well-known risk factors. For these patients, a detailed cardiac examination must be performed and antithrombotic and nitrate prophylaxis should be initiated before chemotherapy regardless of whether or not the cytotoxic agent is known to be cardiotoxic.

**Conclusion**

This case showed that chemotherapeutic agents must be administered with intensive cardiac monitoring especially in patients with cardiac disease and well-known risk factors to prevent the development of cardiac complications, despite an agent not being known to be ‘cardiotoxic’. 

---

Gemcitabine and Coronary Spasm

References


Announcement

14th Health Sciences Center Poster Conference 2009
Faculty of Medicine, Kuwait University, Kuwait, April 21–23, 2009

Announcement and Call for Abstracts

Sponsor: Faculty of Medicine, Kuwait University, Kuwait
Venue: Health Sciences Center, Kuwait University, Kuwait
Deadline for submission of abstracts: January 29, 2009
Abstracts must be submitted online: www.hsc.edu.kw/poster2009 or by E-Mail: poster2009@hsc.edu.kw

Keynote speaker: Prof. R. Brian Haynes, Clinical Epidemiology and Medicine, Health Information Research Unit, Faculty of Health Science, McMaster University, Hamilton, Ontario, Canada
Title: Evidence-Based Medicine and Knowledge Translation Research for Better Health Care
Deadline for registration: Onsite

Poster Awards

A chance to win:
- Dr. Nael Al-Naqeeb Award (for undergraduate students)
- Graduate Award (Basic Sciences)
- Graduate Award (Residents)
- Basic Sciences Award
- Clinical Sciences Award

For further information, contact:
Teena Sadan, Conference Secretary: Tel. +965 249 86418, E-Mail: teena@hsc.edu.kw